# A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)

> **NCT01056159** · PHASE1 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 47 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Albuterol dry powder inhaler
- **DRUG:** Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler)

## Key facts

- **NCT ID:** NCT01056159
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2022-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01056159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01056159, "A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01056159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*